Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03378973 · ClinicalTrials.gov registry record · Phase 4
The Effects of Dexmedetomidine Dose on Motor Evoked Potentials
A Phase 4 study, sponsored by Hospital for Special Surgery, New York.
- Terminated
- Registry status
- Phase 4
- Development phase
- 7
- Enrollment target
NCT03378973: Clinical Trial Phase 4 study, sponsored by Hospital for Special Surgery, New York.
NCT03378973 is a Phase 4 study that was terminated before completion, run by Hospital for Special Surgery, New York. The registered enrollment target is 7 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03378973, a Phase 4 study, was terminated before completion, sponsored by Hospital for Special Surgery, New York.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 7 participants
- Enrollment target
Study Summary
This a parallel group, two-arm, randomized superiority trial that will compare the effect of two different doses of dexmedetomidine on motor evoked potentials during spine surgery
Primary Outcome
Monitorable is defined as stable signals being present in 3 muscles in each lower extremity, with mean peak-to-peak amplitude of at least 50 uV, and with mean-normalized interquartile variability of 0.9 or less.
Interventions
- DRUG Dexmedetomidine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2018-11-28 |
| Est. Completion | 2019-10-17 |
| Phase | Phase 4 |
Why NCT03378973 stopped before completion
NCT03378973 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which Dexmedetomidine is the first listed.
NCT03378973 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03378973 about?
NCT03378973 is a clinical study titled "The Effects of Dexmedetomidine Dose on Motor Evoked Potentials". This a parallel group, two-arm, randomized superiority trial that will compare the effect of two different doses of dexmedetomidine on motor evoked potentials during spine surgery
What is the current status of trial NCT03378973?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 7 participants. The study started on 2018-11-28. Estimated completion is 2019-10-17.
What interventions are being tested in trial NCT03378973?
The interventions under investigation include: Dexmedetomidine (DRUG).
Who is sponsoring clinical trial NCT03378973?
This trial is sponsored by Hospital for Special Surgery, New York, which has 194 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03378973's enrollment target sits among peer trials
7 1981st of 2000 higher than 18 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI